News | May 07, 2021
Lonza announces expansion plans for mammalian manufacturing facilities
The facility is expected to be completed in 2024
The facility is expected to be completed in 2024
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies
Lonza Specialty Ingredients has become LifeClean’s first strategic industrial partner.
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Subscribe To Our Newsletter & Stay Updated
